Acadia Pharma Elects New Directors, Adjusts CMO Compensation
Ticker: ACAD · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1070494
| Field | Detail |
|---|---|
| Company | Acadia Pharmaceuticals Inc (ACAD) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, board-changes, governance
Related Tickers: ACAD
TL;DR
Acadia adds 2 directors, names new audit chair, and gives CMO a new contract with $525k base + bonus.
AI Summary
Acadia Pharmaceuticals Inc. announced on October 28, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. David E. Michelson and Ms. Sarah L. Kelly, and appointed Ms. Kelly as the Chair of the Audit Committee. Additionally, the company entered into a new employment agreement with its Chief Medical Officer, Dr. Jonathan F. F. F. Altarac, effective October 28, 2025, which includes a base salary of $525,000 and potential for an annual bonus.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and financial priorities, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing details routine corporate governance changes and executive compensation adjustments, which are common and typically do not represent significant new risks.
Key Numbers
- $525,000 — CMO Base Salary (New annual base salary for Dr. Altarac effective October 28, 2025.)
- 2 — New Directors (Number of new directors elected to the board.)
Key Players & Entities
- Acadia Pharmaceuticals Inc. (company) — Registrant
- Dr. David E. Michelson (person) — Newly elected director
- Ms. Sarah L. Kelly (person) — Newly elected director and Chair of the Audit Committee
- Dr. Jonathan F. F. F. Altarac (person) — Chief Medical Officer
- $525,000 (dollar_amount) — Chief Medical Officer's new base salary
FAQ
Who were the new directors elected to Acadia's board?
Dr. David E. Michelson and Ms. Sarah L. Kelly were elected as new directors.
What is the new base salary for the Chief Medical Officer?
The new annual base salary for Dr. Jonathan F. F. F. Altarac is $525,000.
When did the new employment agreement for the CMO become effective?
The new employment agreement for Dr. Jonathan F. F. F. Altarac became effective on October 28, 2025.
What is Ms. Sarah L. Kelly's role on the board?
Ms. Sarah L. Kelly was elected as a director and appointed as the Chair of the Audit Committee.
What is the potential for an annual bonus for the CMO?
The filing states that Dr. Jonathan F. F. F. Altarac's new employment agreement includes the potential for an annual bonus, but the specific percentage or target is not detailed in this section.
Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2025-11-03 16:23:34
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar
Filing Documents
- acad-20251028.htm (8-K) — 44KB
- 0001193125-25-262610.txt ( ) — 149KB
- acad-20251028.xsd (EX-101.SCH) — 26KB
- acad-20251028_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acadia Pharmaceuticals Inc. Date: November 3, 2025 By: /s/ Jennifer J. Rhodes Jennifer J. Rhodes Executive Vice President, Chief Legal Officer & Secretary